**OPTIMAL ADHERENCE DURING HCV TREATMENT AMONGST ACTIVE DRUG USERS AT A COMMUNITY BASED PROGRAM IN TORONTO, CANADA**

Powis Ja, Mason Kb, Dodd Zb, Sockalingam Sc, Altenberg Jb

1. Department of Medicine, University of Toronto; Toronto East General Hospital, Toronto, Canada
2. South Riverdale Community Health Centre, Toronto, Canada
3. Department of Psychiatry, University of Toronto; Medical Psychiatry Program, University Health Network, Toronto, Canada

**Background:** Direct acting antiviral (DAA) treatment regimens for Hepatitis C (HCV) are now widely available. Adherence to DAAs is a major predictor of sustained virologic response (SVR), yet few real world trials exist evaluating adherence among people who use drugs. We evaluated adherence among clients receiving DAA treatment from a multidisciplinary, community-based program

**Methods:** This study included chronic HCV patients initiating treatment with DAAs without interferon. A self-report medication adherence questionnaire was completed weekly. Pre/post treatment questionnaires examined socio-demographics, co-morbid conditions and substance use. Optimal adherence was defined has having no days when medication was missed for the intended duration of treatment. Weekly optimal adherence rates were evaluated.

**Results:** 59 participants were enrolled.73% were malewith average age of 53 years. 86% had a history of injection drug use (IDU) with 10% reporting IDU in the past 30 days. 29% reported non-injection illicit drug use (not including marijuana) in the past 30 days and 17% heavy alcohol use in the same period.Treatment regimes included**:** 22% SOF/LED for 8 weeks, 49% SOF/LED for 12 weeks, 2% SOF/LED for 24 weeks; 8% SOF/RBV for 12 weeks and 19% SOF/RBV for 24 weeks. Of the 59 who initiated treatment, 46 completed, 2 discontinued and 11 remain on therapy.Based on intention to treat (ITT), optimal adherence at week 4 & 8 was 50/59 (85%) and 45/59(76%). EOT was 82%(9/11), 76%(22/29), 50%(4/8)% for 8, 12 & 24 treatment durations respectively. EOT responses were available for 39 with an ITT of 95%. SVR rates were available in 17 with an ITT rate of 82%.

**Conclusion:** This study provides insight into the adherence patterns of marginalized people living with HCV and demonstrates that despite high rates of substance use, a community-based model of HCV treatment can support positive HCV treatment outcomes.

**Disclosure:** Nothing to disclose